Evidence map›Paper›PMID 25548186›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.

Roberto A Maldonado, Robert A LaMothe, Joseph D Ferrari, Ai-Hong Zhang, Robert J Rossi, Pallavi N Kolte, Aaron P Griset, Conlin O'Neil, David H Altreuter, Erica Browning and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 253 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
253citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

253 citing papers in PubMed, 1 synthesis or guideline pooled it, 423 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Remote loading of an autoantigen in PLGA nanoparticles for the treatment of multiple sclerosis.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article

193 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Roberto A MaldonadoSelecta Biosciences, Inc., Watertown, MA 02472;
Robert A LaMotheSelecta Biosciences, Inc., Watertown, MA 02472;
Joseph D FerrariSelecta Biosciences, Inc., Watertown, MA 02472;
Ai-Hong ZhangDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814;
Robert J RossiDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814;
Pallavi N KolteSelecta Biosciences, Inc., Watertown, MA 02472;
Aaron P GrisetSelecta Biosciences, Inc., Watertown, MA 02472;
Conlin O'NeilSelecta Biosciences, Inc., Watertown, MA 02472;
David H AltreuterSelecta Biosciences, Inc., Watertown, MA 02472;
Erica BrowningSelecta Biosciences, Inc., Watertown, MA 02472;
Lloyd JohnstonSelecta Biosciences, Inc., Watertown, MA 02472;
Omid C FarokhzadLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; King Abdulaziz University, Jeddah 22254, Saudi Arabia;
Robert LangerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; The David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02139;
David W ScottDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814;
Ulrich H von AndrianDivision of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115-6017; and The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139.
Takashi Kei KishimotoSelecta Biosciences, Inc., Watertown, MA 02472; kkishimoto@selectabio.com.
Selecta Biosciences (United States) · USUniformed Services University of the Health Sciences · USAllen Institute · USBrigham and Women's Hospital · USMassachusetts Institute of Technology · US

Funding

T Cell Activation in Lymph NodesR01AI069259 · NIAID · IMMUNE DISEASE INSTITUTE, INC. · PI VON ANDRIAN, ULRICH H · 2006 to 2015
$4.5M
NIAID NIH HHS R01 AI069259
6 · The paper itself

Abstract

Current treatments to control pathological or unwanted immune responses often use broadly immunosuppressive drugs. New approaches to induce antigen-specific immunological tolerance that control both cellular and humoral immune responses are desirable. Here we describe the use of synthetic, biodegradable nanoparticles carrying either protein or peptide antigens and a tolerogenic immunomodulator, rapamycin, to induce durable and antigen-specific immune tolerance, even in the presence of potent Toll-like receptor agonists. Treatment with tolerogenic nanoparticles results in the inhibition of CD4+ and CD8+ T-cell activation, an increase in regulatory cells, durable B-cell tolerance resistant to multiple immunogenic challenges, and the inhibition of antigen-specific hypersensitivity reactions, relapsing experimental autoimmune encephalomyelitis, and antibody responses against coagulation factor VIII in hemophilia A mice, even in animals previously sensitized to antigen. Only encapsulated rapamycin, not the free form, could induce immunological tolerance. Tolerogenic nanoparticle therapy represents a potential novel approach for the treatment of allergies, autoimmune diseases, and prevention of antidrug antibodies against biologic therapies.

Indexed as

Immune ToleranceAnimalsAntigensCD4-Positive T-LymphocytesDisease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalFactor VIIIFemaleHemocyaninsHemophilia AHumansHypersensitivity, DelayedImmunity, HumoralImmunosuppression TherapyImmunosuppressive AgentsLactic AcidAntigensCPG-oligonucleotideFactor VIIIHemocyaninsImmunosuppressive Agentskeyhole-limpet hemocyaninLactic AcidNanocapsulesOligodeoxyribonucleotidesOvalbuminovalbumin (325-339)Peptide FragmentsPeptidesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerProteinsRecombinant ProteinsSirolimusanti-drug antibodiesimmune toleranceimmunotherapynanoparticlesrapamycin

Identifiers

PMID25548186
PMCPMC4299193
OpenAlexW2092747941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.